Burden of SARS‐CoV‐2 infection prior to vaccine eligibility among immunocompromised children aged 1–11 years at a pediatric tertiary referral hospital in Toronto, Canada

Abstract SARS‐CoV‐2 seroprevalence reflects the efficacy of pandemic infection prevention and control measures. We performed anti‐spike IgG serological testing on residual sera of children 1–11 years old at a tertiary care referral center between October and November 2021. Immunocompromised patients had the highest SARS‐CoV‐2 seroprevalence, at 40.5%, compared to 19.3% in non‐immunocompromised patients. Targeted infection prevention and public health interventions are warranted for pediatric immunocompromised patients in future pandemics.